Cellectis S.A.

NASDAQ:CLLS

Biotechnology

Healthcare
$1.03 -0.65%

-$0.02 today

Market cap
$103.75M
Beta
2.75
P/E (TTM)
-4.6
EPS (TTM)
-$0.67
52W Low $1.35High $5.48

Volume 0.01M

Average 0.04M

CLLS Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Cellectis S.A.NASDAQ: CLLS

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures declines year over year

Q1 FY2026 capital expenditures of $265.97K (cash outflow) fell 32.7% year over year, ahead of the -44.0% change in trailing-twelve-month capital expenditures. Sequentially, it fell 44.4% from the prior quarter. Over 3 fiscal years it compounded at -1.0% a year.

Context

  • Capital expenditures amounted to 3.2% of revenue in FY2025, down 3.0 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -32.7% holds above the trailing-twelve-month pace of -44.0%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$265.97K-44.4% QoQ
Last fiscal yearDec 2025
-$2.37M-8.2% YoY
LTMMar 2026
-$2.23M-44.0% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-32.7%——
1 year-8.2%——
3-year CAGR-1.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(2.37M) USD
Year-over-year change
+8.2%

Capital Expenditures vs competitors

How CLLS compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -44.0% is the 4th highest of 8, against a peer median of -70.3%.
  • Capital expenditures amounts to 3.3% of revenue for CLLS, versus a peer median of 10.9%.
CLLS Competitors
Capital Expenditures for CLLS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
AMRNAmarin Corporation plcLTM Mar 2026$16.69M USD+140168207.3%—7.8%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$6.08M USD—+88.7%—
CLLSCellectis S.A.LTM Mar 2026$2.23M USD-44.0%-1.0%3.3%
DBVTDBV Technologies S.A.LTM Mar 2026$928K USD-8.4%-10.9%—
ACIUAC Immune S.A.LTM Dec 2025CHF 900.16K CHF+56.3%-11.5%25.2%
ANROAlto Neuroscience, Inc.LTM Mar 2026$556K USD-70.3%-68.0%—
KRROKorro Bio, Inc.LTM Mar 2026$420K USD-96.6%-53.7%10.9%
SLNSilence Therapeutics plcLTM Mar 2026$106K USD—-53.4%11.5%
LRMRLarimar Therapeutics, Inc.LTM Mar 2026$42K USD-92.6%-3.1%—
MREOMereo BioPharma Group plcLTM Mar 2026$1.52K USD-99.5%+15.4%0.3%
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$4 USD———
Peer median (excluding CLLS) —-70.3%-11.2%10.9%

Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(96.75M)(98.69M)(116.84M)(36.7M)(67.8M)
Depreciation & Amortization14.16M18.44M18.52M19.84M20.12M
Deferred Income Tax087K371K00
Stock-Based Compensation11.49M6.04M5.23M00
Change in Working Capital(12.3M)(5.72M)(3.99M)53.57M(41.72M)
Accounts Receivables(12.44M)(8.99M)2.25M(6.72M)(4.44M)
Inventory215K0000
Accounts Payables177K3.25M(6.31M)2.05M(3.27M)
Other Working Capital(252K)23K67K58.24M(34.01M)
Other Non-Cash Items(21.17M)(7.6M)71.95M(14.61M)49.26M
Operating Cash Flow(104.56M)(87.44M)(24.75M)22.1M(40.14M)
Capital Expenditures(18.56M)(2.44M)(1.07M)(2.58M)(2.37M)
Acquisitions (Net)00000
Purchases of Investments(143K)00(162.48M)(160.27M)
Sales of Investments15M126K063.69M134.24M
Other Investing Activities10.97M(456K)(14.44M)00
Investing Cash Flow7.28M(2.76M)(15.51M)(102.63M)(29.58M)
Debt Repayment(10.64M)(6.6M)24.56M18.17M(5.4M)
Common Stock Issued44.64M067.94M82.68M44.14K
Common Stock Repurchased0(569K)000
Dividends Paid00000
Other Financing Activities13.53M8.32M(9.64M)(11.04M)(10.85M)
Financing Cash Flow47.53M1.15M82.87M89.8M(16.2M)
Effect of Forex Changes(5.75M)(3.36M)884K(2.73M)6.24M
Net Change in Cash(55.51M)(92.42M)43.49M6.54M(79.67M)
Free Cash Flow(123.12M)(89.89M)(25.82M)19.52M(42.5M)

Cellectis S.A.

NASDAQ:CLLS

Intrinsic Alpha fair value

Locked

Current Price

$1.03

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.